Efgartigimod alfa and hyaluronidase-qvfc - Biologic Drug Details

Summary for efgartigimod alfa and hyaluronidase-qvfc

Tradenames:	1
High Confidence Patents:	0
Applicants:	1
BLAs:	1
Suppliers: see list	1

Pharmacology for efgartigimod alfa and hyaluronidase-qvfc

Mechanism of Action	Neonatal Fc Receptor Blockers
Established Pharmacologic Class	Endoglycosidase Neonatal Fc Receptor Blocker
Chemical Structure	Glycoside Hydrolases

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for efgartigimod alfa and hyaluronidase-qvfc Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for efgartigimod alfa and hyaluronidase-qvfc Derived from DrugPatentWatch Analysis and Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for efgartigimod alfa and hyaluronidase-qvfc Derived from Patent Text Search

No patents found based on company disclosures

Market Dynamics and Financial Trajectory of Efgartigimod Alfa and Hyaluronidase-qvfc

Last updated: February 27, 2026

How does the market for efgartigimod alfa and hyaluronidase-qvfc evolve?

Efgartigimod alfa and hyaluronidase-qvfc operate in distinct segments—autoimmune disorders and subcutaneous enzyme delivery, respectively. Their adoption hinges on their clinical efficacy, approval status, and competitive landscape.

Efgartigimod Alfa

• Indications: Approved for generalized myasthenia gravis (gMG) in the U.S. (August 2021). Under clinical trials for other autoimmune diseases such as pemphigus vulgaris and follicular lymphoma.
• Market Size: The global gMG market was valued at approximately $600 million in 2022, expected to grow at a compound annual growth rate (CAGR) of 8-10% through 2030.
• Drivers:
  • High unmet medical need.
  • Favorable safety profile relative to intravenous immunoglobulin (IVIG).
  • Growing prevalence of autoimmune conditions.
• Challenges:
  • Competition from existing therapies (e.g., rituximab, eculizumab).
  • Price sensitivity among payers.
  • Necessity for chronic treatment compliance.

Hyaluronidase-qvfc

• Indications: Used in subcutaneous fluid and drug delivery, including antibody therapies. Approved in multiple countries as a facilitator of subcutaneous administration.
• Market Size: The global hyaluronidase market was valued at approximately $400 million in 2022, with projected CAGR of 6-7% until 2030.
• Drivers:
  • Increased preference for subcutaneous (SC) administration over intravenous (IV) which enhances patient convenience.
  • Expansion into new therapeutic areas, such as biologic drug delivery.
• Challenges:
  • Competition from other hyaluronidase formulations and enzyme adjuncts.
  • Regulatory hurdles in emerging markets.
  • Patent expirations affecting pricing strategies.

What are the key market adoption and sales projections?

Product	Approximate Market Size (2022)	Projected CAGR (2022-2030)	Main Revenue Drivers
Efgartigimod alfa	$600 million	8-10%	Autoimmune disease prevalence, approval expansion
Hyaluronidase-qvfc	$400 million	6-7%	Growing subcutaneous drug delivery applications

By 2030, efgartigimod alfa's sales could reach $1 billion, assuming market penetration in multiple autoimmune indications. Hyaluronidase-qvfc potentially surpasses $600 million with increased adoption across biologics and therapy facilitation.

Regulatory and reimbursement landscape

• Efgartigimod alfa received FDA approval based on clinical trials demonstrating significant reduction in disease severity scores. Reimbursement policies are emerging, particularly in U.S. and Europe.
• Hyaluronidase-qvfc benefits from broad approval networks, with market access contingent on reimbursement negotiations, particularly in outpatient settings.

Competitive environment

• Efgartigimod alfa faces competitors like eculizumab (Soliris) and rituximab.
• Hyaluronidase-qvfc competes with other enzyme formulations, including recombinant hyaluronidases and emerging delivery-enhancement technologies.

Key financial considerations

• Development costs for efgartigimod alfa likely exceeded $1 billion, considering clinical trials and regulatory processes.
• Market penetration depends heavily on clinical adoption rates, reimbursement policies, and payer coverage.
• Price points for efgartigimod alfa are estimated at approximately $60,000 per year per patient in the U.S., comparable to similar biologic therapies.

Strategic opportunities and risks

Opportunities

• Broader autoimmune indications for efgartigimod alfa.
• Expansion into emerging markets with growing autoimmune disease prevalence.
• Enhancing SC delivery protocols with hyaluronidase-qvfc.

Risks

• Delays in regulatory approvals elsewhere.
• Competitive pressures reducing market share.
• Pricing constraints due to payer negotiations.

Key Takeaways

• Efgartigimod alfa and hyaluronidase-qvfc operate in high-growth segments driven by unmet needs and technological shifts.
• Market size projections suggest strong growth, contingent on approval expansions and clinical adoption.
• Pricing and reimbursement strategies will significantly influence financial trajectories.
• Each product faces competition but benefits from clinical and delivery advantages.
• Market expansion opportunities exist, especially in emerging markets and additional indications.

FAQs

1. What are the primary indications for efgartigimod alfa?
Generalized myasthenia gravis and potential expansion into other autoimmune diseases.

2. How does hyaluronidase-qvfc improve biologic therapy delivery?
It facilitates subcutaneous absorption, allowing larger doses and reducing infusion times.

3. What factors influence the adoption of these biologics?
Clinical efficacy, safety profile, approval status, reimbursement policies, and patient acceptance.

4. Are there regulatory concerns affecting these drugs’ commercialization?
Yes. Efgartigimod alfa has FDA approval but may face additional scrutiny in other regions; hyaluronidase-qvfc has broad approvals but regulatory hurdles remain in some markets.

5. What strategic actions should investors monitor?
Regulatory approvals in new indications, pricing negotiations, and competitive developments in autoimmune and biologic delivery sectors.

---

Sources:

[1] Market Research Future. (2022). Global Hyaluronidase Market Analysis.
[2] Allied Market Research. (2023). Autoimmune Disease Therapeutics Market.
[3] FDA. (2021). Efgartigimod Approval Announcement.
[4] Evaluate Pharma. (2023). Biologic Market Trends.